{"protocolSection":{"identificationModule":{"nctId":"NCT02690155","orgStudyIdInfo":{"id":"18734"},"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Real-world Comparative Effectiveness of Rivaroxaban Versus VKA","officialTitle":"Real-world Comparative Effectiveness of Rivaroxaban Versus VKA","acronym":"RIVA-F"},"statusModule":{"statusVerifiedDate":"2017-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-02-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-03-01","type":"ACTUAL"},"completionDateStruct":{"date":"2016-03-01","type":"ACTUAL"},"studyFirstSubmitDate":"2016-02-19","studyFirstSubmitQcDate":"2016-02-19","studyFirstPostDateStruct":{"date":"2016-02-24","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-04-04","lastUpdatePostDateStruct":{"date":"2017-04-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting"},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Non-valvular atrial fibrillation (NVAF)","Prevention","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":38831,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban","description":"NVAF patients who were initiated on rivaroxaban for stroke prevention","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]},{"label":"VKA (Vitamin K antagonist)","description":"NVAF patients who were initiated on VKA for stroke prevention","interventionNames":["Drug: VKA (Vitamin K antagonist)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"As prescribed by treating physicians","armGroupLabels":["Rivaroxaban"]},{"type":"DRUG","name":"VKA (Vitamin K antagonist)","description":"As prescribed by treating physicians","armGroupLabels":["VKA (Vitamin K antagonist)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Hospitalization Events (composite endpoint)","timeFrame":"Within 2 years of starting treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* NVAF(non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD(International Classification of Disease)-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion\n* Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics\n* CHA2DS2-Vasc score â‰¥2 during the 180 days prior to index rivaroxaban use baseline period (CHA2DS2-Vasc: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65-74 years; Sc: Sex category)\n\nExclusion Criteria:\n\n* Patients \\<18 years of age\n* Patients with valvular AF (Atrial fibrillation)\n* Pregnancy\n* Malignant cancers\n* Transient cause of AF\n* Patients with venous thromboembolism (pulmonary embolism or deep vein thrombosis)\n* Patients with major surgery defined as hip or knee replacement\n* Prescriptions of oral anticoagulants (OACs) (apixaban, warfarin, dabigatran, rivaroxaban) before index date\n* Prescription of more than one OAC on the index date\n* Patient with any of the events defined in the composite endpoint\n\n  * Fatal bleeding\n  * Fatal Stroke/Myocardial infarction\n  * Intracranial hemorrhage\n  * Ischemic stroke\n  * Myocardial infarction","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with non-valvular atrial fibrillation (NVAF)","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"New York","state":"New York","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014812","term":"Vitamin K"},{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000014815","term":"Vitamins"},{"id":"D000018977","term":"Micronutrients"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000000933","term":"Antifibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000006490","term":"Hemostatics"},{"id":"D000003029","term":"Coagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M3942","name":"Antifibrinolytic Agents","relevance":"LOW"},{"id":"M9266","name":"Hemostatics","relevance":"LOW"},{"id":"M5949","name":"Coagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Vi","name":"Vitamins"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}